RTN4R and adenocarcinoma: Specifically, multiple injections of 30 μg doses of tTF-NGR (3–6 times, i.v) in mice xenografted with established human adenocarcinoma (A549), melanoma (M21), or fibrosarcoma (HT1080) resulted in a significant growth inhibition in all three solid tumor models.